ClinicalTrials.gg
TerminatedNCT04465916Updated Nov 2, 2022Results posted

Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)

A Phase 2 interventional study of EYP001a and Placebo in Hepatitis B, Chronic, sponsored by Enyo Pharma. Terminated at 18 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Enyo Pharma · Phase 2, Interventional, and Treatment

Why this study was terminated
DSMC reviewed results of 26 subjects. New randomizations were stopped. Already randomized subjects were followed up to W40.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of — 4 open to participants now, 10 under way, 1 of them phase 3. Hepatitis B, Chronic · Korea, Republic of.

Enrollment
120th of 126
26 · median 106
Started
2020
with 11 others
Phase 2
31 of 149
2 open now
Registered
119th of 149
by date

Among the 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of, this one is the 120th largest by enrollment of the 126 interventional ones that give a count, is one of 12 that started in 2020, is one of 31 in phase 2, and was the 119th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

4 of the 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Hepatitis B, Chronic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically suppressed CHB patients to improve functional cure rates.

Read the detailed description

A total of 49 eligible patients will be enrolled and randomized at approximately 14 study sites. Patients will be randomized prior to study drug (EYP001a or placebo and NA) administration on Day 1 in the ratio of 3:1 into 2 arms:

  • Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)
  • Control Arm: Placebo + NA daily (12 patients)

The maximum total engagement duration for eligible patients in this study is up to 370 days: 90 days screening, 112 days (16 weeks) treatment period and 168 days (24 weeks) follow-up.

Patients enrolled in the study will be assessed as outpatients. Patient screening will occur no more than 90 days prior to the Day 1 visit. Eligible patients will undergo further assessments on Day 1 to qualify for study drug administration on Day 1.

The visits during the study are planned as below:

  • Screening visit: 12 weeks (90 days)
  • 16 weeks treatment period:
  • Treatment Visit 1 (Week 1 [Day 1])
  • Treatment Visit 2 (Week 2 [Day 14 ±3 days])
  • Treatment Visit 3 (Week 4 [Day 28 ±3 days])
  • Treatment Visit 4 (Week 6 [Day 42 ±3 days])
  • Treatment Visit 5 (Week 8 [Day 56 ±3 days])
  • Treatment Visit 6 (Week 10 [Day 70 ± 3 days])
  • Treatment Visit 7 (Week 12 [Day 84 ± 3 days])
  • Treatment Visit 8 (Week 14 [Day 98 ± 3 days])
  • Treatment Visit 9 (Week 16 [Day 112±3 days])
  • 24 weeks safety follow-up period:
  • Follow-up Visit 1 (Week 20 [Day 140 ±7 days])
  • Follow-up Visit 2 (Week 28 [Day 196 ±7 days])
  • Follow-up Visit 3 (Week 40 [Day 280 ±7 days]) Note: during follow-up patients are kept on NA until the end of the trial: Week 40 (consolidation Phase).
03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Are on stable NA therapy at least 12 months from the screening date (ETV or TDF)
  • Has virally suppressed CHB:

\<LLOQ and serum HBsAg >100 IU/mL

  • Has liver imaging to screen for hepatocellular carcinoma or concomitant pancreaticobiliary disease either in the prior 6 months or at screening.
  • Is not of or, if of childbearing potential, is not pregnant as confirmed by a negative serum human chorionic gonadotropin test at screening and is not planning a pregnancy during the course of the study.

Main Exclusion Criteria:

  • Is an employee of a contract research organization (CRO), vendor, or Sponsor involved with this study.
  • Has known hepatocellular carcinoma or pancreaticobiliary disease.
  • Neutropenia (defined by two confirmed values within screening period of \<1500/μL).
  • Has Gilbert syndrome.
  • Shows evidence of worsening liver function, defined as either a confirmed (two assessments at least 3 days apart) increase >2 or AST or an increase of >1.5 × first assessed value of TBL or associated with clinical signs or symptoms of liver impairment.
  • Has known or suspected non-CHB liver disease
  • History of cirrhosis or liver decompensation, including ascites, hepatic encephalopathy, or presence of oesophageal varices.
  • Probable or possible F3 stage with a vibration controlled transient elastography (VCTE). Patients with normal baseline ALT and VCTE >8.8 kPa are excluded. Patients with baseline ALT >ULN (but \<2ULN per EC5) and who have VCTE >10.5 kPa at baseline are excluded 11.
  • Has known history of alcohol abuse or daily heavy alcohol consumption
  • Has , including, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.
  • Has used anti-HBV medications other than NAs within 90 days prior to screening.
  • Has any of the following exclusionary laboratory results at screening:

    1. Estimated \<60 mL/min/1.73 m2 (the Modification of Diet in Renal Disease formula).
    2. Thyroid-stimulating hormone >1.5× ULN or abnormal free triiodothyronine or free thyroxine.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)

    Drug: EYP001a · Drug: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)

  • Placebo comparator
    Control Arm

    Control Arm: Placebo + NA daily (12 patients)

    Drug: Placebo · Drug: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)

Interventions

  • Oral tablets

  • DrugPlacebo

    Oral tablets

  • DrugNucleotide analogue (Entecavir or Tenofovir Disoproxil)

    Oral tablets

06

What researchers measure

Primary outcomes

  1. HBsAg Change (Δ log10) From Day 1 to Week 16 of Treatment

    Efficacy of Vonafexor on top of NA assessed as HBsAg decline (Δ log10) from Day 1 to Week 16 of treatment

    Time frame: LS mean at week 16 (Day 1, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12, Week 14, and Week 16)

Secondary outcomes

  1. Virologic Failure Rate

    Virologic failure rate (breakthrough)2 of HBV-DNA (% patients with a confirmed quantifiable HBV DNA increase of ≥ 1log10 HBV DNA copies/mL above LLOQ3) assessed at Week 16 of treatment period and Weeks 20, 28 and 40 during follow-up period

    Time frame: 40 weeks

07

Results

Posted Oct 12, 2022

Participant flow

Participant flow — Overall Study
MilestoneExperimental ArmControl Arm
Started197
Completed196
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryHBsAg Change (Δ log10) From Day 1 to Week 16 of Treatment

Efficacy of Vonafexor on top of NA assessed as HBsAg decline (Δ log10) from Day 1 to Week 16 of treatment

Time frame:
LS mean at week 16 (Day 1, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12, Week 14, and Week 16)
Reported as:
Least squares mean · log10 IU/mL
HBsAg Change (Δ log10) From Day 1 to Week 16 of Treatment
log10 IU/mLExperimental ArmControl Arm
HBsAg Change (Δ log10) From Day 1 to Week 16 of Treatment-0.029 ± 0.0195-0.066 ± 0.0348
SecondaryVirologic Failure Rate

Virologic failure rate (breakthrough)2 of HBV-DNA (% patients with a confirmed quantifiable HBV DNA increase of ≥ 1log10 HBV DNA copies/mL above LLOQ3) assessed at Week 16 of treatment period and Weeks 20, 28 and 40 during follow-up period

Time frame:
40 weeks
Reported as:
Number · participants
Virologic Failure Rate
participantsExperimental ArmControl Arm
Week 1600
Week 2000
Week 2800
Week 4000

Adverse events

Collected over After the first dose of study drug until W40. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Arm0/19 (0%)0/19 (0%)17/19 (89.5%)
Control Arm0/7 (0%)0/7 (0%)3/7 (42.9%)
Most frequent other events
Showing 10 of 29
Most frequent other events
EventExperimental ArmControl Arm
PruritusSkin and subcutaneous tissue disorders15/191/7
DiarrhoeaGastrointestinal disorders3/190/7
Serum ferritin decreasedInvestigations0/191/7
White blood cell count decreasedInvestigations0/191/7
Atrioventricular block first degreeCardiac disorders0/191/7
NeutropeniaBlood and lymphatic system disorders0/191/7
Abdominal pain lowerGastrointestinal disorders0/191/7
Hiatus herniaGastrointestinal disorders0/191/7
OesophagitisGastrointestinal disorders0/191/7
NauseaGastrointestinal disorders2/190/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Experimental ArmControl ArmTotal
Geometric mean45.16 ± 8.3246.29 ± 8.4645.46 ± 8.20
Sex: Female, Male
Sex: Female, Male(Participants)Experimental ArmControl ArmTotal
Female516
Male14620
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Experimental ArmControl ArmTotal
Asian19524
Black or African American011
White011
Weight
Weight(kg)Experimental ArmControl ArmTotal
Geometric mean68.821 ± 11.29382.857 ± 21.08472.600 ± 15.454
Height
Height(cm)Experimental ArmControl ArmTotal
Geometric mean168.763 ± 9.333172.529 ± 11.342169.777 ± 9.823
08

Study locations

18 sites
  • ENYO PHARMA Investigative site AU02
    Brisbane, Australia
  • ENYO PHARMA Investigative site AU01
    Melbourne, Australia
  • ENYO PHARMA Investigative site AU03
    Melbourne, Australia
  • ENYO PHARMA Investigative site AU04
    Melbourne, Australia
  • ENYO PHARMA Investigative site HK01
    Hong Kong, Hong Kong
  • ENYO PHARMA Investigative site KR04
    Pusan, Korea, Republic of
  • ENYO PHARMA Investigative site KR07
    Pusan, Korea, Republic of
  • ENYO PHARMA Investigative site KR05
    Seongnam, Korea, Republic of
  • ENYO PHARMA Investigative site KR01
    Seoul, Korea, Republic of
  • ENYO PHARMA Investigative site KR02
    Seoul, Korea, Republic of
  • ENYO PHARMA Investigative site KR03
    Seoul, Korea, Republic of
  • ENYO PHARMA Investigative site KR06
    Séoul, Korea, Republic of
  • ENYO PHARMA Investigative site PL01
    Białystok, Poland
  • ENYO PHARMA Investigative site PL06
    Kielce, Poland
  • ENYO PHARMA Investigative site PL02
    Lublin, Poland
  • ENYO PHARMA Investigative site PL03
    Warszawa, Poland
  • ENYO PHARMA Investigative site PL04
    Zawiercie, Poland
  • ENYO PHARMA Investigative site PL05
    Łódź, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Jun 2021, 13 months.

Results were first posted in Oct 2022, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2020
First posted
Jul 10, 2020
StartActual
May 12, 2020
Primary completionActual
Jun 17, 2021
CompletionActual
Nov 25, 2021
Results first posted
Oct 12, 2022
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04465916
Lead sponsor
Enyo Pharma
Collaborators
Novotech (Australia) Pty Limited, Synteract, Inc., Eurofins, Parexel
Responsible party
Sponsor
First posted
Jul 10, 2020
Start date
May 12, 2020
Primary completion
Jun 17, 2021
Completion
Nov 25, 2021
Results posted
Oct 12, 2022
Last update
Nov 2, 2022

Study contacts

ENYO PHARMA Investigative site KR04
principal investigator · Pusan, South Korea
ENYO PHARMA Investigative site KR03
principal investigator · Seoul, South Korea
ENYO PHARMA Investigative site KR02
principal investigator · Seoul, South Korea
ENYO PHARMA Investigative site KR01
principal investigator · Seoul, South Korea
ENYO PHARMA Investigative site PL06
principal investigator · Kielce, Poland
ENYO PHARMA Investigative site PL05
principal investigator · Łódź, Poland
ENYO PHARMA Investigative site PL04
principal investigator · Zawiercie, Poland
ENYO PHARMA Investigative site PL03
principal investigator · Warszawa, Poland
ENYO PHARMA Investigative site PL02
principal investigator · Lublin, Poland
ENYO PHARMA Investigative site PL01
principal investigator · Białystok, Poland
ENYO PHARMA Investigative site AU04
principal investigator · Melbourne, Australia
ENYO PHARMA Investigative site AU03
principal investigator · Melbourne, Australia
ENYO PHARMA Investigative site AU02
principal investigator · Brisbane, Australia
ENYO PHARMA Investigative site AU01
principal investigator · Melbourne, Australia
ENYO PHARMA Investigative site HK01
principal investigator · Hong Kong, Hong Kong
ENYO PHARMA Investigative site KR05
principal investigator · Seongnam, South Korea
ENYO PHARMA Investigative site KR06
principal investigator · Séoul, South Korea
ENYO PHARMA Investigative site KR07
principal investigator · Pusan, South Korea

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EYP001A

Start the discussion